3SBio Inc (SEHK:1530)

APAC company
add to virtual portfolio
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - 1530

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - 1530

  • Market CapHKD0.000m
  • SymbolSEHK:1530
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINKYG8875G1029

Company Profile

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2018, it reported revenue of CNY 4.6 billion. Approximately 75% of its revenue is derived from three core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), and EPIAO (rhEPO), which are all older generation biologics. The company has a pipeline of 32 products, of which 22 are biologics and 10 are small molecules. Only two of these products are expected to launch within the next year: inetetamab (biosimilar of trastuzumab, a HER2 down-regulator) and Jiantuoxi (biosimilar of rituximab, an anti-CD20 antibody).3SBio Inc is a part of the Chinese healthcare sector. Its business comprises of developing and marketing pharmaceutical products in China. Its main products include TPIAO and Yisaipu.

Latest 1530 news

Currently there for this company. Visit our news hub for other news .